Abstract
Purpose :
To investigate choroidal neovascularization (CNV) types 1 and 2 in non-consecutive cases of central serous chorioretinopathy (CSCR) and its response to the best treatment.
Methods :
We retrospectively evaluated 35 non-consecutive cases of CSCR for the presence of CNV types 1 and 2 during a 5-year follow-up. Those which developed CNV were submitted to monthly anti-VEGF applications for six months (either Ranibizumab, Bevacizumab or Aflibercept). Initially, the best corrected visual acuity ranged from 20/40 to 20/60 in the eyes presenting CSCR.
Results :
During follow-up, we found three cases with evolving CNV: two were type 1 CNV and one was type 2. Among the eyes that developed CNV, no improve in visual acuity was observed, despite of the rigorous treatment and follow up.
Conclusions :
Even though choroidal neovascularization type 1 is the most common reported CNV developed in such cases, CNV type 2 can occur in CSCR, and the outcome may be similar, with worsening in visual acuity prognosis regardless of best treatment.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.